teleo-codex/domains/health/glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population.md

type	domain	description	confidence	source	created	title	agent	sourced_from	scope	sourcer	supports	related	reweave_edges
claim	health	Atypical anorexics meet diagnostic criteria for anorexia nervosa despite normal or elevated BMI, making them appear as ideal GLP-1 candidates to prescribers using BMI-based screening alone	experimental	Dr. Kim Dennis (eating disorder specialist), NPR investigation	2026-05-05	GLP-1 prescribing creates systematic screening gap for atypical anorexia because normal BMI masks active restrictive psychopathology	vida	health/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md	structural	NPR (@NPRHealth)	glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive GLP-1 adolescent prescribing requires eating disorder screening because subclinical restrictive behaviors are clinically invisible without structured assessment	glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring	GLP-1 adolescent prescribing requires eating disorder screening because subclinical restrictive behaviors are clinically invisible without structured assessment|supports|2026-05-07

GLP-1 prescribing creates systematic screening gap for atypical anorexia because normal BMI masks active restrictive psychopathology

Dr. Kim Dennis identifies atypical anorexia as a specific high-risk population for GLP-1 harm that standard screening protocols fail to detect. Atypical anorexia nervosa is characterized by meeting full diagnostic criteria for anorexia nervosa—including restrictive eating patterns, fear of weight gain, and body image disturbance—while maintaining a BMI in the normal or overweight range. This creates a dangerous screening gap: these patients appear as textbook GLP-1 candidates based on BMI criteria alone, but have active eating disorder psychopathology that GLP-1's appetite suppression will exacerbate. The article notes that 'nearly a tenth of people will meet the clinical benchmarks of an eating disorder at some point in their lives,' creating substantial overlap with the obesity treatment population. Dr. Samantha DeCaro emphasizes that eating disorders involve 'emotional, relational, and biological drivers' that weight loss alone does not address. The structural problem is that BMI-based eligibility screening—the primary gate for GLP-1 access—is precisely the metric that makes atypical anorexia invisible. This is distinct from general eating disorder risk: it's a population-specific screening failure where the diagnostic tool (BMI) actively obscures the contraindication.